{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:03:49Z","timestamp":1794269029456,"version":"4.9.0"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The INBUILD trial was funded by Boehringer Ingelheim International GmbH (BI).","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2022,2,12]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Living with Pulmonary Fibrosis (L-PF) questionnaire assesses symptoms and quality of life in patients with fibrosing interstitial lung diseases (ILDs). Its Dyspnoea and Cough domains, whose items\u2019 responses are based on a 24-hour recall, have scores ranging from 0 to 100, with higher scores indicating greater symptom severity. We evaluated the ability of these domain scores to detect change and estimated their meaningful change thresholds in patients with progressive fibrosing ILDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The INBUILD trial enrolled subjects with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis. The L-PF questionnaire was completed at baseline and week 52. The responsiveness of the Dyspnoea and Cough scores was evaluated by comparing changes in these scores with 52-week changes in three anchors: forced vital capacity % predicted and two self-reported items, one for global physical health and one for global quality of life. We used a triangulation approach including anchor-based and distribution-based methods to estimate meaningful change thresholds.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analyses included 542 subjects with an L-PF Dyspnoea score at baseline and week 52, and 538 subjects with an L-PF Cough score at baseline and week 52. The L-PF Dyspnoea and Cough scores were responsive to change over 52 weeks. Triangulation of anchor-based and distribution-based estimates resulted in meaningful change thresholds of 6 to 7 points for the L-PF Dyspnoea score and 4 to 5 points for the L-PF Cough score to differentiate subjects who were stable or improved from those who deteriorated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These analyses support the responsiveness, one aspect of validity, of the L-PF Dyspnoea and Cough domains scores as measures of symptom severity in patients with progressive fibrosing ILDs. Estimates for meaningful change thresholds in these domain scores may be of value in interpreting the effects of interventions in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02999178\">NCT02999178<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2021-001167","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T11:06:20Z","timestamp":1646305580000},"page":"e001167","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02999178","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-8110","authenticated-orcid":false,"given":"Jeffrey J","family":"Swigris","sequence":"first","affiliation":[{"name":"National Jewish Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M","family":"Bushnell","sequence":"additional","affiliation":[{"name":"Evidera (Pharmaceutical Product Development, LLC), Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Rohr","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Mueller","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"2025083110530129000_9.1.e001167.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2025083110530129000_9.1.e001167.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020"},{"key":"2025083110530129000_9.1.e001167.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"2025083110530129000_9.1.e001167.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020"},{"key":"2025083110530129000_9.1.e001167.5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018"},{"key":"2025083110530129000_9.1.e001167.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS\u00ae trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"2025083110530129000_9.1.e001167.7","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-020-01570-2","article-title":"Determinants of health-related quality of life decline in interstitial lung disease","volume":"18","author":"Maqhuzu","year":"2020","journal-title":"Health Qual Life Outcomes"},{"key":"2025083110530129000_9.1.e001167.8","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American thoracic Society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110530129000_9.1.e001167.9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the living with idiopathic pulmonary fibrosis questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083110530129000_9.1.e001167.10","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00145-2020"},{"key":"2025083110530129000_9.1.e001167.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00044-1"},{"key":"2025083110530129000_9.1.e001167.12","unstructured":"Food and Drug Administration . Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available: https:\/\/www.fda.gov\/media\/77832\/download"},{"key":"2025083110530129000_9.1.e001167.13","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0026-2021"},{"key":"2025083110530129000_9.1.e001167.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025083110530129000_9.1.e001167.15","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.200410135"},{"key":"2025083110530129000_9.1.e001167.16","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199905000-00006"},{"key":"2025083110530129000_9.1.e001167.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00071-2"},{"key":"2025083110530129000_9.1.e001167.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"2025083110530129000_9.1.e001167.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00435-3"},{"key":"2025083110530129000_9.1.e001167.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(96)70135-5"},{"key":"2025083110530129000_9.1.e001167.21","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"2025083110530129000_9.1.e001167.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025083110530129000_9.1.e001167.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025083110530129000_9.1.e001167.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025083110530129000_9.1.e001167.25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025083110530129000_9.1.e001167.26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2025083110530129000_9.1.e001167.27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-Term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025083110530129000_9.1.e001167.28","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210035"},{"key":"2025083110530129000_9.1.e001167.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"key":"2025083110530129000_9.1.e001167.30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2025083110530129000_9.1.e001167.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000278"},{"key":"2025083110530129000_9.1.e001167.32","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01359-3","article-title":"Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis","volume":"21","author":"Prior","year":"2020","journal-title":"Respir Res"},{"key":"2025083110530129000_9.1.e001167.33","doi-asserted-by":"crossref","DOI":"10.1177\/14799731211033925","article-title":"Psychometric properties of patient reported outcome measures in idiopathic pulmonary fibrosis","volume":"18","author":"Kim","year":"2021","journal-title":"Chron Respir Dis"},{"key":"2025083110530129000_9.1.e001167.34","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20120002"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2021-001167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T17:53:11Z","timestamp":1756662791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2021-001167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,3]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjresp-2021-001167"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2021-001167","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}